clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00065442 |
P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
P582 | end time | 2009-01-01 | |
P921 | main subject | cancer immunotherapy | Q2012719 |
P1050 | medical condition | metastatic prostate carcinoma | Q55779807 |
prostate neoplasm | Q56014511 | ||
P2899 | minimum age | 18 | |
P1132 | number of participants | 512 | |
P4844 | research intervention | sipuleucel-T | Q424057 |
P6153 | research site | New York University | Q49210 |
University of Cincinnati | Q153265 | ||
University of Washington | Q219563 | ||
University of Minnesota | Q238101 | ||
University of Wisconsin–Madison | Q838330 | ||
Mayo Clinic | Q1130172 | ||
Dana–Farber Cancer Institute | Q1159198 | ||
Indiana University – Purdue University Indianapolis | Q1433199 | ||
Rush University Medical Center | Q1535116 | ||
Loyola University Chicago | Q1537759 | ||
Virginia Mason Medical Center | Q7934403 | ||
Nevada Cancer Institute | Q16932830 | ||
Cancer Care Northwest | Q30269598 | ||
Rocky Mountain Cancer Centers | Q30270311 | ||
Urology Associates of North Texas | Q30270635 | ||
Duke University Medical Center | Q30279912 | ||
Sharp HealthCare Foundation | Q30288725 | ||
Northwell Health Orthopaedic Institute | Q33122159 | ||
University of Utah Health Care | Q56582915 | ||
Icahn School of Medicine at Mount Sinai | Q1950740 | ||
Baylor College of Medicine | Q2892284 | ||
New York Medical College | Q4115972 | ||
Cleveland Clinic | Q4117596 | ||
P859 | sponsor | Dendreon | Q5256667 |
P580 | start time | 2003-07-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Randomized, Double Blind, Placebo Controlled Phase 3 Trial of Immunotherapy With Autologous Antigen Presenting Cells Loading With PA2024 (Provenge(R), APC8015) in Men With Metastatic Androgen Independent Prostatic Adenocarcinoma |
Search more.